



Universiteit  
Leiden  
The Netherlands

## **Allosteric Modulation of 'Reproductive' GPCRs : a case for the GnRH and LH receptors**

Heitman, L.H.

### **Citation**

Heitman, L. H. (2009, April 22). *Allosteric Modulation of 'Reproductive' GPCRs : a case for the GnRH and LH receptors*. Retrieved from <https://hdl.handle.net/1887/13748>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13748>

**Note:** To cite this publication please use the final published version (if applicable).

---

## REFERENCES

- (1) Hargrave, P. A.; McDowell, J. H.; Curtis, D. R.; Wang, J. K.; Juszczak, E.; Fong, S. L.; Rao, J. K.; Argos, P. The structure of bovine rhodopsin. *Biophys Struct Mech* **1983**, *9*, 235-244.
- (2) Consortium, I. H. G. S. Finishing the euchromatic sequence of the human genome. *Nature* **2004**, *431*, 931-945.
- (3) Gloriam, D. E.; Fredriksson, R.; Schiöth, H. B. The G protein-coupled receptor subset of the rat genome. *BMC Genomics* **2007**, *8*, 338-354.
- (4) Foord, S. M.; Bonner, T. I.; Neubig, R. R.; Rosser, E. M.; Pin, J. P.; Davenport, A. P.; Spedding, M.; Harmar, A. J. International Union of Pharmacology. XLVI. G protein-coupled receptor list. *Pharmacol Rev* **2005**, *57*, 279-288.
- (5) Patrick, G. L. *An introduction to medicinal chemistry*. 2<sup>nd</sup> ed.; Oxford, 2001.
- (6) Strange, P. G. Signaling mechanisms of GPCR ligands. *Curr Opin Drug Discov Devel* **2008**, *11*, 196-202.
- (7) Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schiöth, H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. *Mol Pharmacol* **2003**, *63*, 1256-1272.
- (8) Malnic, B.; Hirono, J.; Sato, T.; Buck, L. B. Combinatorial receptor codes for odors. *Cell* **1999**, *96*, 713-723.
- (9) Kunishima, N.; Shimada, Y.; Tsuji, Y.; Sato, T.; Yamamoto, M.; Kumasaka, T.; Nakanishi, S.; Jingami, H.; Morikawa, K. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. *Nature* **2000**, *407*, 971-977.
- (10) Millar, R. P.; Lu, Z. L.; Pawson, A. J.; Flanagan, C. A.; Morgan, K.; Maudsley, S. R. Gonadotropin-releasing hormone receptors. *Endocr Rev* **2004**, *25*, 235-275.
- (11) Knollman, P. E.; Conn, P. M. Multiple G proteins compete for binding with the human gonadotropin releasing hormone receptor. *Arch Biochem Biophys* **2008**, *477*, 92-97.
- (12) Lagerström, M. C.; Schiöth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery. *Nat Rev Drug Discov* **2008**, *7*, 339-357.
- (13) Ji, T. H.; Grossmann, M.; Ji, I. G protein-coupled receptors. I. Diversity of receptor-ligand interactions. *J Biol Chem* **1998**, *273*, 17299-17302.
- (14) Betz, S. F.; Zhu, Y. F.; Chen, C.; Struthers, R. S. Non-peptide gonadotropin-releasing hormone receptor antagonists. *J Med Chem* **2008**, *51*, 3331-3348.
- (15) Hsu, S. Y.; Liang, S. G.; Hsueh, A. J. Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region. *Mol Endocrinol* **1998**, *12*, 1830-1845.
- (16) Hsu, S. Y.; Kudo, M.; Chen, T.; Nakabayashi, K.; Bhalla, A.; van der Spek, P. J.; van Duin, M.; Hsueh, A. J. The three subfamilies of leucine-rich repeat-containing G protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7. *Mol Endocrinol* **2000**, *14*, 1257-1271.
- (17) Hsu, S. Y. New insights into the evolution of the relaxin-LGR signaling system. *Trends Endocrinol Metab* **2003**, *14*, 303-309.
- (18) Vassart, G.; Pardo, L.; Costagliola, S. A molecular dissection of the glycoprotein hormone receptors. *Trends Biochem Sci* **2004**, *29*, 119-126.
- (19) <http://www.iuphar-db.org/GPCR/ReceptorListForward>.
- (20) Bruysters, M.; Verhoef-Post, M.; Themmen, A. P. Asp330 and Tyr331 in the C-terminal cysteine-rich region of the luteinizing hormone receptor are key residues in hormone-induced receptor activation. *J Biol Chem* **2008**, *283*, 25821-25828.

- (21) Van Straten, N. C.; Schoonus-Gerritsma, G. G.; van Someren, R. G.; Draaijer, J.; Adang, A. E.; Timmers, C. M.; Hanssen, R. G.; van Boeckel, C. A. The first orally active low molecular weight agonists for the LH receptor: thienopyr(im)idines with therapeutic potential for ovulation induction. *Chembiochem* **2002**, *3*, 1023-1026.
- (22) Wise, A.; Gearing, K.; Rees, S. Target validation of G-protein coupled receptors. *Drug Discov Today* **2002**, *7*, 235-246.
- (23) Schmid, E. F.; Smith, D. A. Keynote review: Is declining innovation in the pharmaceutical industry a myth? *Drug Discov Today* **2005**, *10*, 1031-1039.
- (24) <http://www.phrma.org/>.
- (25) Costa, T.; Herz, A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. *Proc Natl Acad Sci U S A* **1989**, *86*, 7321-7325.
- (26) Kjelsberg, M. A.; Cotecchia, S.; Ostrowski, J.; Caron, M. G.; Lefkowitz, R. J. Constitutive activation of the  $\alpha_{1B}$ -adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. *J Biol Chem* **1992**, *267*, 1430-1433.
- (27) Costa, T.; Cotecchia, S. Historical review: Negative efficacy and the constitutive activity of G-protein-coupled receptors. *Trends Pharmacol Sci* **2005**, *26*, 618-624.
- (28) Bond, R. A.; IJzerman, A. P. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. *Trends Pharmacol Sci* **2006**, *27*, 92-96.
- (29) Smit, M. J.; Vischer, H. F.; Bakker, R. A.; Jongejan, A.; Timmerman, H.; Pardo, L.; Leurs, R. Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity. *Ann Rev Pharm Tox* **2007**, *47*, 53-87.
- (30) Fotiadis, D.; Liang, Y.; Filipek, S.; Saperstein, D. A.; Engel, A.; Palczewski, K. Atomic-force microscopy: Rhodopsin dimers in native disc membranes. *Nature* **2003**, *421*, 127-128.
- (31) White, J. H.; Wise, A.; Main, M. J.; Green, A.; Fraser, N. J.; Disney, G. H.; Barnes, A. A.; Emson, P.; Foord, S. M.; Marshall, F. H. Heterodimerization is required for the formation of a functional GABA<sub>B</sub> receptor. *Nature* **1998**, *396*, 679-682.
- (32) Jordan, B. A.; Cvejic, S.; Devi, L. A. Opioids and their complicated receptor complexes. *Neuropsychopharmacology* **2000**, *23*, S5-S18.
- (33) Milligan, G. G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. *Drug Discov Today* **2006**, *11*, 541-549.
- (34) Sun, Y.; McGarrigle, D.; Huang, X. Y. When a G protein-coupled receptor does not couple to a G protein. *Mol Biosyst* **2007**, *3*, 849-854.
- (35) Violin, J. D.; Lefkowitz, R. J.  $\beta$ -Arrestin-biased ligands at seven-transmembrane receptors. *Trends Pharmacol Sci* **2007**, *28*, 416-422.
- (36) Van Koppen, C.; Zaman, G.; Timmers, C.; Kelder, J.; Mosselman, S.; van de Lagemaat, R.; Smit, M. J.; Hanssen, R. A signaling-selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor. *Naunyn Schmiedeberg's Arch Pharmacol* **2008**, *378*, 503-514.
- (37) Woo, A. Y.-H.; Wang, T.-B.; Zeng, X.; Zhu, W.; Abernethy, D. R.; Wainer, I. W.; Xiao, R.-P. Stereochemistry of an agonist determines coupling preference of  $\beta_2$ -adrenoceptor to different G proteins in cardiomyocytes. *Mol Pharmacol* **2009**, *75*, 158-165.
- (38) Levoe, A.; Dam, J.; Ayoub, M. A.; Guillaume, J. L.; Jockers, R. Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers. *Embo Reports* **2006**, *7*, 1094-1098.
- (39) Levoe, A.; Dam, J.; Ayoub, M. A.; Guillaume, J. L.; Couturier, C.; Delagrangue, P.; Jockers, R. The orphan GPR50 receptor specifically inhibits MT<sub>1</sub> melatonin receptor function through heterodimerization. *EMBO J* **2006**, *25*, 3012-3023.
- (40) Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. *Science* **2000**, *289*, 739-745.

- (41) Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H.-J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human  $\beta_2$ -adrenergic G protein coupled receptor. *Science* **2007**, *318*, 1258-1265.
- (42) Rasmussen, S. G. F.; Choi, H.-J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R. P.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F. X.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human  $\beta_2$  adrenergic G-protein-coupled receptor. *Nature* **2007**, *450*, 383-387
- (43) Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G. W.; Tate, C. G.; Schertler, G. F. X. Structure of a  $\beta_1$ -adrenergic G-protein-coupled receptor. *Nature* **2008**, *454*, 486-491.
- (44) Magnani, F.; Shibata, Y.; Serrano-Vega, M. J.; Tate, C. G. Co-evolving stability and conformational homogeneity of the human adenosine  $A_{2a}$  receptor. *Proc Natl Acad Sci U S A* **2008**, *105*, 10744-10749.
- (45) Jaakola, V. P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y.; Lane, J. R.; IJzerman, A. P.; Stevens, R. C. The 2.6 angstrom crystal structure of a human  $A_{2A}$  adenosine receptor bound to an antagonist. *Science* **2008**, *322*, 1211-1217.
- (46) Monod, J.; Changeux, J. P.; Jacob, F. Allosteric proteins and cellular control systems. *J Mol Biol* **1963**, *6*, 306-329.
- (47) Ehlert, F. J. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. *Mol Pharmacol* **1985**, *28*, 410-421.
- (48) Brady, A. E.; Limbird, L. E. G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. *Cell Signal* **2002**, *14*, 297-309.
- (49) May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors. *Ann Rev Pharm Tox* **2007**, *47*, 1-51.
- (50) Liu, Y.; Teeter, M. M.; DuRand, C. J.; Neve, K. A. Identification of a  $Zn^{2+}$ -binding site on the dopamine  $D_2$  receptor. *Biochem Biophys Res Commun* **2006**, *339*, 873-879.
- (51) Lanzafame, A. A.; Guida, E.; Christopoulos, A. Effects of anandamide on the binding and signaling properties of  $M_1$  muscarinic acetylcholine receptors. *Biochem Pharmacol* **2004**, *68*, 2207-2219.
- (52) Bacman, S. R.; Berra, A.; Sterin-Borda, L.; Borda, E. S. Human primary Sjögren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. *Curr Eye Res* **1998**, *17*, 1135-1142.
- (53) Sullivan, S. K.; Brown, M. S.; Gao, Y.; Loweth, C. J.; Lio, F. M.; Crowe, P. D.; Struthers, R. S.; Betz, S. F. Allosteric and orthosteric binding modes of two nonpeptide human gonadotropin-releasing hormone receptor antagonists. *Biochemistry* **2006**, *45*, 15327-15337.
- (54) Yanofsky, S. D.; Shen, E. S.; Holden, F.; Whitehorn, E.; Aguilar, B.; Tate, E.; Holmes, C. P.; Scheuerman, R.; MacLean, D.; Wu, M. M.; Frail, D. E.; Lopez, F. J.; Winneker, R.; Arey, B. J.; Barrett, R. W. Allosteric activation of the follicle-stimulating hormone (FSH) receptor by selective, nonpeptide agonists. *J Biol Chem* **2006**, *281*, 13226-13233.
- (55) Arey, B. J. Allosteric modulators of glycoprotein hormone receptors: discovery and therapeutic potential. *Endocrinology* **2009**, doi: 10.1007/s12020-008-9098-2.
- (56) Neubig, R. R.; Spedding, M.; Kenakin, T.; Christopoulos, A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. *Pharmacol Rev* **2003**, *55*, 597-606.
- (57) Rees, S.; Morrow, D.; Kenakin, T. GPCR drug discovery through the exploitation of allosteric drug binding sites. *Receptors Channels* **2002**, *8*, 261-268.
- (58) Christopoulos, A.; Kenakin, T. G protein-coupled receptor allosterism and complexing. *Pharmacol Rev* **2002**, *54*, 323-374.
- (59) Black, J. W.; Leff, P. Operational models of pharmacological agonism. *Proc R Soc Lond B Biol Sci* **1983**, *220*, 141-162.

- (60) Ehlert, F. J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. *Mol Pharmacol* **1988**, *33*, 187-194.
- (61) Hall, D. A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. *Mol Pharmacol* **2000**, *58*, 1412-1423.
- (62) Lazareno, S.; Popham, A.; Birdsall, N. J. Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-<sup>3</sup>H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. *Mol Pharmacol* **2000**, *58*, 194-207.
- (63) Durroux, T. Principles: A model for the allosteric interactions between ligand binding sites within a dimeric GPCR. *Trends Pharmacol Sci* **2005**, *26*, 376-384.
- (64) Tyndall, J. D.; Sandilya, R. GPCR agonists and antagonists in the clinic. *Med Chem* **2005**, *1*, 405-421.
- (65) Franceschini, N.; Joy, M. S.; Kshirsagar, A. Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism. *Expert Opin Investig Drugs* **2003**, *12*, 1413-1421.
- (66) Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. *Antimicrob Agents Chemother* **2005**, *49*, 4721-4732.
- (67) Bridges, T. M.; Lindsley, C. W. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. *ACS Chem Biol* **2008**, *3*, 530-541.
- (68) Göblyös, A.; IJzerman, A. P. Allosteric modulation of adenosine receptors. *Purinergic Signal*. **2008**.
- (69) Van de Lagemaat, R.; Timmers, C. M.; Kelder, J.; Van Koppen, C.; Mosselman, S.; Hanssen, R. G. Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor. *Hum Reprod* **2009**, *24*, 640-648.
- (70) Struthers, R. S.; Chen, T.; Campbell, B.; Jimenez, R.; Pan, H.; Yen, S. S.; Bozigian, H. P. Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902). *J Clin Endocrinol Metab* **2006**, *91*, 3903-3907.
- (71) Papanikolaou, E. G.; Kolibianakis, E.; Devroey, P. Emerging drugs in assisted reproduction. *Expert Opin Emerg Drugs* **2005**, *10*, 425-440.
- (72) Kiesel, L. A.; Rody, A.; Greb, R. R.; Szilagyi, A. Clinical use of GnRH analogues. *Clin Endocrinol* **2002**, *56*, 677-687.
- (73) Weckermann, D.; Harzmann, R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. *Eur Urol* **2004**, *46*, 279-83; discussion 283-4.
- (74) Engel, J. B.; Schally, A. V. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. *Nat Clin Pract Endocrinol Metab* **2007**, *3*, 157-167.
- (75) White, C. D.; Stewart, A. J.; Lu, Z. L.; Millar, R. P.; Morgan, K. Antiproliferative effects of GnRH agonists: Prospects and problems for cancer therapy. *Neuroendocrinology* **2008**, *88*, 67-79.
- (76) <http://www.clinicaltrials.gov>.
- (77) Klein, J.; Lobel, L.; Pollak, S.; Lustbader, B.; Ogden, R. T.; Sauer, M. V.; Lustbader, J. W. Development and characterization of a long-acting recombinant hFSH agonist. *Hum Reprod* **2003**, *18*, 50-56.
- (78) Bouloux, P. M.; Handelsman, D. J.; Jockenhovel, F.; Nieschlag, E.; Rabinovici, J.; Frasa, W. L.; de Bie, J. J.; Voortman, G.; Itskovitz-Eldor, J. First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. *Hum Reprod* **2001**, *16*, 1592-1597.
- (79) Orvieto, R. Can we eliminate severe ovarian hyperstimulation syndrome? *Hum Reprod* **2005**, *20*, 320-322.
- (80) Choi, J. H.; Wong, A. S.; Huang, H. F.; Leung, P. C. Gonadotropins and ovarian cancer. *Endocr Rev* **2007**, *28*, 440-461.

- (81) Janssens, J. P.; Russo, J.; Russo, I.; Michiels, L.; Donders, G.; Verjans, M.; Riphagen, I.; Van den Bossche, T.; Deleu, M.; Sieprath, P. Human chorionic gonadotropin (hCG) and prevention of breast cancer. *Mol Cell Endocrinol* **2007**, *269*, 93-98.
- (82) Fanelli, F.; Puett, D. Structural aspects of luteinizing hormone receptor. *Endocrine* **2002**, *18*, 285-293.
- (83) Kakar, S. S.; Musgrove, L. C.; Devor, D. C.; Sellers, J. C.; Neill, J. D. Cloning, sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor. *Biochem Biophys Res Commun* **1992**, *189*, 289-295.
- (84) Chi, L.; Zhou, W.; Prikhozhan, A.; Flanagan, C.; Davidson, J. S.; Golembo, M.; Illing, N.; Millar, R. P.; Sealfon, S. C. Cloning and characterization of the human GnRH receptor. *Mol Cell Endocrinol* **1993**, *91*, R1-6.
- (85) Minegishi, T.; Nakamura, K.; Takakura, Y.; Miyamoto, K.; Hasegawa, Y.; Ibuki, Y.; Igarashi, M.; Minegishi, T. Cloning and sequencing of human LH/hCG receptor cDNA. *Biochem Biophys Res Commun* **1990**, *172*, 1049-1054.
- (86) Minegishi, T.; Nakamura, K.; Takakura, Y.; Ibuki, Y.; Igarashi, M.; Minegishi, T. Cloning and sequencing of human FSH receptor cDNA. *Biochem Biophys Res Commun* **1991**, *175*, 1125-1130.
- (87) Lee, D. K.; Nguyen, T.; O'Neill, G. P.; Cheng, R.; Liu, Y.; Howard, A. D.; Coulombe, N.; Tan, C. P.; Tang-Nguyen, A. T.; George, S. R.; O'Dowd, B. F. Discovery of a receptor related to the galanin receptors. *FEBS Lett* **1999**, *446*, 103-107.
- (88) Themmen, A. P. N.; Huhtaniemi, I. T. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. *Endocr Rev* **2000**, *21*, 551-583.
- (89) Rhoades, R.; Pflanzner, R. *Human physiology*. Harcourt Inc.: Orlando, 1996; p pp 915-918.
- (90) Kotani, M.; Detheux, M.; Vandenbogaerde, A.; Communi, D.; Vanderwinden, J. M.; Le Poul, E.; Brezillon, S.; Tyldesley, R.; Suarez-Huerta, N.; Vandeput, F.; Blanpain, C.; Schiffmann, S. N.; Vassart, G.; Parmentier, M. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. *J Biol Chem* **2001**, *276*, 34631-34636.
- (91) Messenger, S.; Chatzidaki, E. E.; Ma, D.; Hendrick, A. G.; Zahn, D.; Dixon, J.; Thresher, R. R.; Malinge, I.; Lomet, D.; Carlton, M. B.; Colledge, W. H.; Caraty, A.; Aparicio, S. A. Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. *Proc Natl Acad Sci U S A* **2005**, *102*, 1761-1766.
- (92) Leuschner, C.; Hansel, W. Targeting breast and prostate cancers through their hormone receptors. *Biol Reprod* **2005**, *73*, 860-865.
- (93) Mead, E. J.; Maguire, J. J.; Kuc, R. E.; Davenport, A. P. Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. *Br J Pharmacol* **2007**, *151*, 1143-1153.
- (94) Belchetz, P. E.; Plant, T. M.; Nakai, Y.; Keogh, E. J.; Knobil, E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. *Science* **1978**, *202*, 631-633.
- (95) Conn, P. M.; Crowley, W. F., Jr. Gonadotropin-releasing hormone and its analogs. *Annu Rev Med* **1994**, *45*, 391-405.
- (96) Huirne, J. A.; Lambalk, C. B. Gonadotropin-releasing-hormone-receptor antagonists. *Lancet* **2001**, *358*, 1793-1803.
- (97) Herbst, K. L. Gonadotropin-releasing hormone antagonists. *Curr Opin Pharmacol* **2003**, *3*, 660-666.
- (98) Cho, N.; Harada, M.; Imaeda, T.; Imada, T.; Matsumoto, H.; Hayase, Y.; Sasaki, S.; Furuya, S.; Suzuki, N.; Okubo, S.; Ogi, K.; Endo, S.; Onda, H.; Fujino, M. Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. *J Med Chem* **1998**, *41*, 4190-4195.

- (99) Karten, M. J.; Rivier, J. E. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. *Endocr Rev* **1986**, *7*, 44-66.
- (100) Imada, T.; Cho, N.; Imaeda, T.; Hayase, Y.; Sasaki, S.; Kasai, S.; Harada, M.; Matsumoto, H.; Endo, S.; Suzuki, N.; Furuya, S. Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists. *J Med Chem* **2006**, *49*, 3809-3825.
- (101) DeVita, R. J.; Hollings, D. D.; Goulet, M. T.; Wyvratt, M. J.; Fisher, M. H.; Lo, J. L.; Yang, Y. T.; Cheng, K.; Smith, R. G. Identification and initial structure-activity relationships of a novel non-peptide quinolone GnRH receptor antagonist. *Bioorg Med Chem Lett* **1999**, *9*, 2615-2620.
- (102) Young, J. R.; Huang, S. X.; Chen, I.; Walsh, T. F.; DeVita, R. J.; Wyvratt, M. J., Jr.; Goulet, M. T.; Ren, N.; Lo, J.; Yang, Y. T.; Yudkovitz, J. B.; Cheng, K.; Smith, R. G. Quinolones as gonadotropin releasing hormone (GnRH) antagonists: simultaneous optimization of the C(3)-aryl and C(6)-substituents. *Bioorg Med Chem Lett* **2000**, *10*, 1723-1727.
- (103) DeVita, R. J.; Goulet, M. T.; Wyvratt, M. J.; Fisher, M. H.; Lo, J. L.; Yang, Y. T.; Cheng, K.; Smith, R. G. Investigation of the 4-O-alkylamine substituent of non-peptide quinolone GnRH receptor antagonists. *Bioorg Med Chem Lett* **1999**, *9*, 2621-2624.
- (104) Walsh, T. F.; Toupence, R. B.; Young, J. R.; Huang, S. X.; Ujjainwalla, F.; DeVita, R. J.; Goulet, M. T.; Wyvratt, M. J., Jr.; Fisher, M. H.; Lo, J. L.; Ren, N.; Yudkovitz, J. B.; Yang, Y. T.; Cheng, K.; Smith, R. G. Potent antagonists of gonadotropin releasing hormone receptors derived from quinolone-6-carboxamides. *Bioorg Med Chem Lett* **2000**, *10*, 443-447.
- (105) DeVita, R. J.; Walsh, T. F.; Young, J. R.; Jiang, J.; Ujjainwalla, F.; Toupence, R. B.; Parikh, M.; Huang, S. X.; Fair, J. A.; Goulet, M. T.; Wyvratt, M. J.; Lo, J. L.; Ren, N.; Yudkovitz, J. B.; Yang, Y. T.; Cheng, K.; Cui, J.; Mount, G.; Rohrer, S. P.; Schaeffer, J. M.; Rhodes, L.; Drisko, J. E.; McGowan, E.; MacIntyre, D. E.; Vincent, S.; Carlin, J. R.; Cameron, J.; Smith, R. G. A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptor. *J Med Chem* **2001**, *44*, 917-922.
- (106) DeVita, R. J.; Parikh, M.; Jiang, J.; Fair, J. A.; Young, J. R.; Walsh, T. F.; Goulet, M. T.; Lo, J. L.; Ren, N.; Yudkovitz, J. B.; Cui, J.; Yang, Y. T.; Cheng, K.; Rohrer, S. P.; Wyvratt, M. J. Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists. *Bioorg Med Chem Lett* **2004**, *14*, 5599-5603.
- (107) Chu, L.; Hutchins, J. E.; Weber, A. E.; Lo, J. L.; Yang, Y. T.; Cheng, K.; Smith, R. G.; Fisher, M. H.; Wyvratt, M. J.; Goulet, M. T. Initial structure-activity relationship of a novel class of nonpeptidyl GnRH receptor antagonists: 2-arylindoles. *Bioorg Med Chem Lett* **2001**, *11*, 509-513.
- (108) Chu, L.; Lo, J. L.; Yang, Y. T.; Cheng, K.; Smith, R. G.; Fisher, M. H.; Wyvratt, M. J.; Goulet, M. T. SAR studies of novel 5-substituted 2-arylindoles as nonpeptidyl GnRH receptor antagonists. *Bioorg Med Chem Lett* **2001**, *11*, 515-517.
- (109) Lin, P.; Marino, D.; Lo, J. L.; Yang, Y. T.; Cheng, K.; Smith, R. G.; Fisher, M. H.; Wyvratt, M. J.; Goulet, M. T. 2-(3,5-Dimethylphenyl)tryptamine derivatives that bind to the GnRH receptor. *Bioorg Med Chem Lett* **2001**, *11*, 1073-1076.
- (110) Lin, P.; Parikh, M.; Lo, J. L.; Yang, Y. T.; Cheng, K.; Smith, R. G.; Fisher, M. H.; Wyvratt, M. J.; Goulet, M. T. Heterocyclic derivatives of 2-(3,5-dimethylphenyl)tryptamine as GnRH receptor antagonists. *Bioorg Med Chem Lett* **2001**, *11*, 1077-1080.
- (111) Ashton, W. T.; Sisco, R. M.; Yang, Y. T.; Lo, J. L.; Yudkovitz, J. B.; Cheng, K.; Goulet, M. T. Substituted indole-5-carboxamides and -acetamides as potent nonpeptide GnRH receptor antagonists. *Bioorg Med Chem Lett* **2001**, *11*, 1723-1726.
- (112) Ashton, W. T.; Sisco, R. M.; Yang, Y. T.; Lo, J. L.; Yudkovitz, J. B.; Gibbons, P. H.; Mount, G. R.; Ren, R. N.; Butler, B. S.; Cheng, K.; Goulet, M. T. Potent nonpeptide GnRH receptor antagonists

- derived from substituted indole-5-carboxamides and -acetamides bearing a pyridine side-chain terminus. *Bioorg Med Chem Lett* **2001**, *11*, 1727-1731.
- (113) Ashton, W. T.; Sisco, R. M.; Kieczkowski, G. R.; Yang, Y. T.; Yudkovitz, J. B.; Cui, J.; Mount, G. R.; Ren, R. N.; Wu, T. J.; Shen, X.; Lyons, K. A.; Mao, A. H.; Carlin, J. R.; Karanam, B. V.; Vincent, S. H.; Cheng, K.; Goulet, M. T. Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity. *Bioorg Med Chem Lett* **2001**, *11*, 2597-2602.
- (114) Young, J. R.; Huang, S. X.; Walsh, T. F.; Wyvratt, M. J.; Yang, Y. T.; Yudkovitz, J. B.; Cui, J.; Mount, G. R.; Ren, R. N.; Wu, T. J.; Shen, X.; Lyons, K. A.; Mao, A. H.; Carlin, J. R.; Karanam, B. V.; Vincent, S. H.; Cheng, K.; Goulet, M. T. 2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain. *Bioorg Med Chem Lett* **2002**, *12*, 827-832.
- (115) Simeone, J. P.; Bugianesi, R. L.; Ponpipom, M. M.; Yang, Y. T.; Lo, J. L.; Yudkovitz, J. B.; Cui, J.; Mount, G. R.; Ren, R. N.; Creighton, M.; Mao, A. H.; Vincent, S. H.; Cheng, K.; Goulet, M. T. Modification of the pyridine moiety of non-peptidyl indole GnRH receptor antagonists. *Bioorg Med Chem Lett* **2002**, *12*, 3329-3332.
- (116) Zhu, Y. F.; Struthers, R. S.; Connors, P. J., Jr.; Gao, Y.; Gross, T. D.; Saunders, J.; Wilcoxon, K.; Reinhart, G. J.; Ling, N.; Chen, C. Initial structure-activity relationship studies of a novel series of pyrrolo[1,2-a]pyrimid-7-ones as GnRH receptor antagonists. *Bioorg Med Chem Lett* **2002**, *12*, 399-402.
- (117) Zhu, Y. F.; Wilcoxon, K.; Saunders, J.; Guo, Z.; Gao, Y.; Connors, P. J., Jr.; Gross, T. D.; Tucci, F. C.; Struthers, R. S.; Reinhart, G. J.; Xie, Q.; Chen, C. A novel synthesis of 2-arylpyrrolo[1,2-a]pyrimid-7-ones and their structure-activity relationships as potent GnRH receptor antagonists. *Bioorg Med Chem Lett* **2002**, *12*, 403-406.
- (118) Tucci, F. C.; Zhu, Y. F.; Guo, Z.; Gross, T. D.; Connors, P. J., Jr.; Struthers, R. S.; Reinhart, G. J.; Wang, X.; Saunders, J.; Chen, C. A novel synthesis of 7-aryl-8-fluoro-pyrrolo[1,2-a]pyrimid-4-ones as potent, stable GnRH receptor antagonists. *Bioorg Med Chem Lett* **2002**, *12*, 3491-3495.
- (119) Perrin, M. H.; Haas, Y.; Rivier, J. E.; Vale, W. W. Gonadotropin-releasing hormone binding to rat anterior pituitary membrane homogenates. Comparison of antagonists and agonists using radiolabeled antagonist and agonist. *Mol Pharmacol* **1983**, *23*, 44-51.
- (120) Sasaki, S.; Imaeda, T.; Hayase, Y.; Shimizu, Y.; Kasai, S.; Cho, N.; Harada, M.; Suzuki, N.; Furuya, S.; Fujino, M. A new class of potent nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists: design and synthesis of 2-phenylimidazo[1,2-a]pyrimidin-5-ones. *Bioorg Med Chem Lett* **2002**, *12*, 2073-2077.
- (121) Wilcoxon, K. M.; Zhu, Y. F.; Connors, P. J.; Saunders, J.; Gross, T. D.; Gao, Y.; Reinhart, G. J.; Struthers, R. S.; Chen, C. Synthesis and initial structure-activity relationships of a novel series of imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists. *Bioorg Med Chem Lett* **2002**, *12*, 2179-2183.
- (122) Gross, T. D.; Zhu, Y. F.; Saunders, J.; Wilcoxon, K. M.; Gao, Y.; Connors, P. J., Jr.; Guo, Z.; Struthers, R. S.; Reinhart, G. J.; Chen, C. Design, synthesis and structure-activity relationships of novel imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists. *Bioorg Med Chem Lett* **2002**, *12*, 2185-2187.
- (123) Zhu, Y. F.; Guo, Z.; Gross, T. D.; Gao, Y.; Connors, P. J., Jr.; Struthers, R. S.; Xie, Q.; Tucci, F. C.; Reinhart, G. J.; Wu, D.; Saunders, J.; Chen, C. Design and structure-activity relationships of 2-alkyl-3-aminomethyl-6-(3-methoxyphenyl)-7-methyl-8-(2-fluorobenzyl)imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists. *J Med Chem* **2003**, *46*, 1769-1772.
- (124) Sasaki, S.; Cho, N.; Nara, Y.; Harada, M.; Endo, S.; Suzuki, N.; Furuya, S.; Fujino, M. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. *J Med Chem* **2003**, *46*, 113-124.

- (125) Guo, Z.; Chen, Y.; Wu, D.; Zhu, Y. F.; Struthers, R. S.; Saunders, J.; Xie, Q.; Chen, C. Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidine-2,4-dione derivatives as potent GnRH receptor antagonists. *Bioorg Med Chem Lett* **2003**, *13*, 3617-3622.
- (126) Luthin, D. R.; Hong, Y.; Pathak, V. P.; Paderes, G.; Nared-Hood, K. D.; Castro, M. A.; Vazir, H.; Li, H.; Tompkins, E.; Christie, L.; May, J. M.; Anderson, M. B. The discovery of novel small molecule non-peptide gonadotropin releasing hormone (GnRH) receptor antagonists. *Bioorg Med Chem Lett* **2002**, *12*, 3467-3470.
- (127) Luthin, D. R.; Hong, Y.; Tompkins, E.; Anderes, K. L.; Paderes, G.; Kraynov, E. A.; Castro, M. A.; Nared-Hood, K. D.; Castillo, R.; Gregory, M.; Vazir, H.; May, J. M.; Anderson, M. B. Characterization of mono- and diaminopyrimidine derivatives as novel, nonpeptide gonadotropin releasing hormone (GnRH) receptor antagonists. *Bioorg Med Chem Lett* **2002**, *12*, 3635-3639.
- (128) Anderes, K. L.; Luthin, D. R.; Castillo, R.; Kraynov, E. A.; Castro, M.; Nared-Hood, K.; Gregory, M. L.; Pathak, V. P.; Christie, L. C.; Paderes, G.; Vazir, H.; Ye, Q.; Anderson, M. B.; May, J. M. Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. *J Pharmacol Exp Ther* **2003**, *305*, 688-695.
- (129) Li, H.; Anderes, K. L.; Kraynov, E. A.; Luthin, D. R.; Do, Q. Q.; Hong, Y.; Tompkins, E.; Sun, E. T.; Rajapakse, R.; Pathak, V. P.; Christie, L. C.; Vazir, H.; Castillo, R.; Gregory, M. L.; Castro, M.; Nared-Hood, K.; Paderes, G.; Anderson, M. B. Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist. *J Med Chem* **2006**, *49*, 3362-3367.
- (130) Zhu, Y. F.; Gross, T. D.; Guo, Z.; Connors, P. J., Jr.; Gao, Y.; Tucci, F. C.; Struthers, R. S.; Reinhart, G. J.; Saunders, J.; Chen, T. K.; Killam Bonneville, A. L.; Chen, C. Identification of 1-arylmethyl-3-(2-aminoethyl)-5-aryluracil as novel gonadotropin-releasing hormone receptor antagonists. *J Med Chem* **2003**, *46*, 2023-2026.
- (131) Guo, Z.; Zhu, Y. F.; Tucci, F. C.; Gao, Y.; Struthers, R. S.; Saunders, J.; Gross, T. D.; Xie, Q.; Reinhart, G. J.; Chen, C. Synthesis and structure-activity relationships of 1-arylmethyl-3-(2-aminopropyl)-5-aryl-6-methyluracils as potent GnRH receptor antagonists. *Bioorg Med Chem Lett* **2003**, *13*, 3311-3315.
- (132) Tucci, F. C.; Zhu, Y. F.; Guo, Z.; Gross, T. D.; Connors, P. J., Jr.; Struthers, R. S.; Reinhart, G. J.; Saunders, J.; Chen, C. Synthesis and structure-activity relationships of 1-arylmethyl-3-(1-methyl-2-amino)ethyl-5-aryl-6-methyluracils as antagonists of the human GnRH Receptor. *Bioorg Med Chem Lett* **2003**, *13*, 3317-3322.
- (133) Guo, Z.; Zhu, Y. F.; Gross, T. D.; Tucci, F. C.; Gao, Y.; Moorjani, M.; Connors, P. J., Jr.; Rowbottom, M. W.; Chen, Y.; Struthers, R. S.; Xie, Q.; Saunders, J.; Reinhart, G.; Chen, T. K.; Bonneville, A. L.; Chen, C. Synthesis and structure-activity relationships of 1-arylmethyl-5-aryl-6-methyluracils as potent gonadotropin-releasing hormone receptor antagonists. *J Med Chem* **2004**, *47*, 1259-1271.
- (134) Tucci, F. C.; Zhu, Y. F.; Guo, Z.; Gross, T. D.; Connors, P. J., Jr.; Gao, Y.; Rowbottom, M. W.; Struthers, R. S.; Reinhart, G. J.; Xie, Q.; Chen, T. K.; Bozigian, H.; Killam Bonneville, A. L.; Fisher, A.; Jin, L.; Saunders, J.; Chen, C. 3-(2-aminoalkyl)-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)-6-methyl-uracils as orally bioavailable antagonists of the human gonadotropin releasing hormone receptor. *J Med Chem* **2004**, *47*, 3483-3486.
- (135) Rowbottom, M. W.; Tucci, F. C.; Connors, P. J., Jr.; Gross, T. D.; Zhu, Y. F.; Guo, Z.; Moorjani, M.; Acevedo, O.; Carter, L.; Sullivan, S. K.; Xie, Q.; Fisher, A.; Struthers, R. S.; Saunders, J.; Chen, C. Synthesis and structure-activity relationships of uracil derived human GnRH receptor antagonists: (R)-3-[2-(2-amino)phenethyl]-1-(2,6-difluorobenzyl)-6-methyluracils containing a substituted thiophene or thiazole at C-5. *Bioorg Med Chem Lett* **2004**, *14*, 4967-4973.
- (136) Rowbottom, M. W.; Tucci, F. C.; Zhu, Y. F.; Guo, Z.; Gross, T. D.; Reinhart, G. J.; Xie, Q.; Struthers, R. S.; Saunders, J.; Chen, C. Synthesis and structure-activity relationships of (R)-1-alkyl-3-[2-(2-amino)phenethyl]-5-(2-fluorophenyl)-6-methyluracils as human GnRH receptor antagonists. *Bioorg Med Chem Lett* **2004**, *14*, 2269-2274.

- (137) Tucci, F. C.; Zhu, Y. F.; Struthers, R. S.; Guo, Z.; Gross, T. D.; Rowbottom, M. W.; Acevedo, O.; Gao, Y.; Saunders, J.; Xie, Q.; Reinhart, G. J.; Liu, X. J.; Ling, N.; Bonneville, A. K.; Chen, T.; Bozigian, H.; Chen, C. 3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. design, synthesis, and in vitro and in vivo characterization. *J Med Chem* **2005**, *48*, 1169-1178.
- (138) Guo, Z.; Chen, Y.; Huang, C. Q.; Gross, T. D.; Pontillo, J.; Rowbottom, M. W.; Saunders, J.; Struthers, S.; Tucci, F. C.; Xie, Q.; Wade, W.; Zhu, Y. F.; Wu, D.; Chen, C. Uracils as potent antagonists of the human gonadotropin-releasing hormone receptor without atropisomers. *Bioorg Med Chem Lett* **2005**, *15*, 2519-2522.
- (139) Zhao, L.; Guo, Z.; Chen, Y.; Hu, T.; Wu, D.; Zhu, Y.-F.; Rowbottom, M.; Gross, T. D.; Tucci, F. C.; Struthers, R. S.; Xie, Q.; Chen, C. 5-Aryluracils as potent GnRH antagonists — Characterization of atropisomers. *Bioorg Med Chem Lett* **2008**, *18*, 3344-3349.
- (140) Chen, C.; Chen, Y.; Pontillo, J.; Guo, Z.; Huang, C. Q.; Wu, D.; Madan, A.; Chen, T.-K.; Wen, J.; Xie, Q.; Tucci, F. C.; Rowbottom, M.; Zhu, Y.-F.; Wade, W.; Saunders, J.; Bozigian, H. P.; Struthers, R. S. Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity. *Bioorg Med Chem Lett* **2008**, *18*, 3301-3305.
- (141) Regan, C. F.; Guo, Z.; Chen, Y.; Huang, C. Q.; Chen, M.; Jiang, W.; Rueter, J. K.; Coon, T.; Chen, C.; Saunders, J.; Brown, M. S.; Betz, S. F.; Struthers, R. S.; Yang, C.; Wen, J.; Madan, A.; Zhu, Y.-F. Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties. *Bioorg Med Chem Lett* **2008**, *18*, 4503-4507.
- (142) Flanagan, C. A.; Fromme, B. J.; Davidson, J. S.; Millar, R. P. A high affinity gonadotropin-releasing hormone (GnRH) tracer, radioiodinated at position 6, facilitates analysis of mutant GnRH receptors. *Endocrinology* **1998**, *139*, 4115-4119.
- (143) Hovelmann, S.; Hoffmann, S. H.; Kuhne, R.; ter Laak, T.; Reilander, H.; Beckers, T. Impact of aromatic residues within transmembrane helix 6 of the human gonadotropin-releasing hormone receptor upon agonist and antagonist binding. *Biochemistry* **2002**, *41*, 1129-1136.
- (144) Struthers, R. S.; Xie, Q.; Sullivan, S. K.; Reinhart, G. J.; Kohout, T. A.; Zhu, Y.-F.; Chen, C.; Liu, X.-J.; Ling, N.; Yang, W.; Maki, R. A.; Bonneville, A. K.; Chen, T.-K.; Bozigian, H. P. Pharmacological Characterization of a Novel Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor, NBI-42902. *Endocrinology* **2007**, *148*, 857-867.
- (145) Hoffmann, S. H.; ter Laak, T.; Kuhne, R.; Reilander, H.; Beckers, T. Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding. *Mol Endocrinol* **2000**, *14*, 1099-1115.
- (146) Kohout, T. A.; Xie, Q.; Reijmers, S.; Finn, K. J.; Guo, Z.; Zhu, Y. F.; Struthers, R. S. Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism. *Mol Pharmacol* **2007**, *72*, 238-247.
- (147) Hashimoto, K.; Tatsuta, M.; Kataoka, M.; Yasoshima, K.; Shogase, Y.; Shimazaki, M.; Yura, T.; Li, Y.; Yamamoto, N.; Gupta, J. B.; Urbahns, K. Benzimidazole derivatives as novel nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 1: Benzimidazole-5-sulfonamides. *Bioorg Med Chem Lett* **2005**, *15*, 799-803.
- (148) Li, Y.; Kataoka, M.; Tatsuta, M.; Yasoshima, K.; Yura, T.; Urbahns, K.; Kiba, A.; Yamamoto, N.; Gupta, J. B.; Hashimoto, K. Benzimidazole derivatives as novel nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 2: Benzimidazole-5-sulfonamides. *Bioorg Med Chem Lett* **2005**, *15*, 805-807.
- (149) Pelletier, J. C.; Chengalvala, M.; Cottom, J.; Feingold, I.; Garrick, L.; Green, D.; Hauze, D.; Huselton, C.; Jetter, J.; Kao, W.; Kopf, G. S.; Lundquist Iv, J. T.; Mann, C.; Mehlmann, J.; Rogers, J.; Shanno, L.; Wrobel, J. 2-Phenyl-4-piperazinybenzimidazoles: Orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor. *Bioorg Med Chem* **2008**, *16*, 6617-6640.

- (150) Guo, Z.; Wu, D.; Zhu, Y. F.; Tucci, F. C.; Pontillo, J.; Saunders, J.; Xie, Q.; Struthers, R. S.; Chen, C. A convenient one-pot synthesis of asymmetric 1,3,5-triazine-2,4,6-triones and its application towards a novel class of gonadotropin-releasing hormone receptor antagonists. *Bioorg Med Chem Lett* **2005**, *15*, 693-698.
- (151) Guo, Z.; Wu, D.; Zhu, Y. F.; Tucci, F. C.; Regan, C. F.; Rowbottom, M. W.; Struthers, R. S.; Xie, Q.; Reijmers, S.; Sullivan, S. K.; Sai, Y.; Chen, C. Structure-activity relationships of 1,3,5-triazine-2,4,6-triones as human gonadotropin-releasing hormone receptor antagonists. *Bioorg Med Chem Lett* **2005**, *15*, 3685-3690.
- (152) Pontillo, J.; Chen, C. Efficient synthesis of bicyclic oxazolino- and thiazolino[3,2-c]pyrimidine-5,7-diones and its application to the synthesis of GnRH antagonists. *Bioorg Med Chem Lett* **2005**, *15*, 1407-1411.
- (153) Pontillo, J.; Guo, Z.; Wu, D.; Struthers, R. S.; Chen, C. Synthesis of aryl-1,2,4-triazine-3,5-diones as antagonists of the gonadotropin-releasing hormone receptor. *Bioorg Med Chem Lett* **2005**, *15*, 4363-4366.
- (154) Lanier, M. C.; Feher, M.; Ashweek, N. J.; Loweth, C. J.; Rueter, J. K.; Slee, D. H.; Williams, J. P.; Zhu, Y.-F.; Sullivan, S. K.; Brown, M. S. Selection, synthesis, and structure-activity relationship of tetrahydropyrido[4,3-d]pyrimidine-2,4-diones as human GnRH receptor antagonists. *Bioorg Med Chem* **2007**, *15*, 5590-5603.
- (155) Chen, M.; Guo, Z.; Lanier, M. C.; Zhao, L.; Betz, S. F.; Huang, C. Q.; Loweth, C. J.; Ashweek, N. J.; Liu, X. J.; Struthers, R. S.; Bradbury, M. J.; Behan, J. W.; Wen, J.; O'Brien, Z.; Saunders, J.; Zhu, Y. F. Identification of 2-(4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-ethylamine derivatives as novel GnRH receptor antagonists. *Bioorg Med Chem Lett* **2007**, *17*, 3845-3850.
- (156) Arnould, J. C.; Delouvie, B.; Boutron, P.; Dossetter, A. G.; Foote, K. M.; Hamon, A.; Hancox, U.; Harris, C. S.; Hutton, M.; Lamorlette, M.; Matusiak, Z. Synthesis and structure-activity relationships of thieno[2,3-b]pyrroles as antagonists of the GnRH receptor. *Bioorg Med Chem Lett* **2007**, *17*, 6448-6454.
- (157) Chen, C.; Wu, D.; Guo, Z.; Rowbottom, M. Gonadotropin-releasing hormone receptor antagonists. *WO 2003011293* **2003**.
- (158) Tucci, F. C.; Connors, P. J.; Zhu, Y.-F.; Chen, C. Preparation of substituted pyridin-4-ones as gonadotropin-releasing hormone receptor (GnRH) antagonists for treating sex-hormone related conditions. *WO 2003013528* **2003**.
- (159) Bird, T. G. C.; Herdemann, M. F.; Maudet, M. L. P. Preparation of pyrazole derivatives as antagonists of gonadotropin releasing hormone (gnrh) for treating sex hormone related conditions. . *WO 2004017961* **2004**.
- (160) Bird, T. G. C.; Maudet, M. L. P. Preparation of substituted pyrazole derivatives as GnRH inhibitors. *WO 2004018459* **2004**.
- (161) Harris, C. S. Preparation of pyrroles as gonadotropin releasing hormone (gnrh) antagonists for treating sex-hormone related conditions. *WO 2005079805* **2005**.
- (162) Showell, G. A.; Miller, D. J.; Glen, A.; Cubillo de Dios, M. A.; Merchant, K.; Mandal, A. K. Heterocyclic non-peptide GnRH antagonists and their preparation, pharmaceutical compositions and use as disease preventive agents. . *WO 2007000582* **2007**.
- (163) Haviv, F.; Dwight, W. J.; Crawford, B. W.; Swenson, R. E.; Bruncko, M.; Kaminski, M. A.; Frey, L. M.; Demattei, J.; Greer, J. Preparation of tetrahydroisoquinoline derivatives as LHRH antagonists. . *US 5981521*.
- (164) Haviv, F.; Dwight, W. J.; Crawford, B. W.; Swenson, R. E.; Bruncko, M.; Kaminski, M. A.; Frey, L. M.; Demattei, J.; Greer, J. Preparation of phenylpropionylaminodiphenylalkyltetrahydroisoquinolines and related compounds as LHRH antagonists. *WO 2000029380* **2000**.

- (165) Hirano, M.; Kawaminami, E.; Toyoshima, A.; Moritomo, H.; Seki, N.; Wakayama, R.; Okada, M.; Kusayama, T. Preparation of 2-(benzoazolidinylene)propane-1,3-dione derivatives as GnRH receptor antagonists. *WO 2002002533* **2002**.
- (166) Hirano, M.; Kawaminami, E.; Kinoyama, I.; Matsumoto, S.; Ohnuki, K.; Obitsu, K.; Kusayama, T. Preparation of benzimidazole derivatives as GnRH receptor antagonists. *WO 2005118556* **2005**.
- (167) Hirano, M.; Kinoyama, I.; Matsumoto, S.; Kawaminami, E.; Ohnuki, K.; Yamamoto, H.; Osoda, K.; Takahashi, T.; Shin, T.; Koike, T.; Shimada, I.; Hisamichi, H.; Kusayama, T. Preparation of dihydrobenzimidazole moiety-containing propane-1,3-dione derivatives as GnRH receptor antagonists. *WO 2006106812* **2006**.
- (168) Peng, G.; Gallop, M. A.; Chernov-Rogan, T.; Yanofsky, S. D.; Pelletier, J. C.; Green, D. M. Novel bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists. *US 2002065309* **2002**.
- (169) Peng, G.; Gallop, M. A.; Chernov-Rogan, T.; Yanovsky, S.; Pelletier, J. C.; Green, D. M. Novel bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists. *WO 2002011732* **2002**.
- (170) Sui, Z.; Macielag, M.; Lanter, J. C. 7-Heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives useful as antagonists of gonadotropin releasing hormone. *WO 2002048112* **2002**.
- (171) Strehlke, P.; Droescher, P.; Buehmann, U.; Schmees, N.; Muhn, P.; Hess-Stumpp, H.; Kuehne, R.; Guenther, E.; Polymeropoulos, E.; Ter Laak, A. M. Preparation of quinolines, isoquinolines and phthalazines as GnRH antagonists. *DE 10108271* **2002**.
- (172) Strehlke, P.; Droescher, P.; Buehmann, U.; Schmees, N.; Muhn, P.; Hess-Stumpp, H.; Kuehne, R.; Guenther, E.; Polymeropoulos, E.; Ter Laak, A. M. Preparation of quinolines, isoquinolines and phthalazines as GnRH antagonists. *WO 2002066437* **2002**.
- (173) Dossetter, A. G.; Kenny, P.; McKerrecher, D.; Wardleworth, M. Preparation of substituted imidazopyridines for antagonizing gonadotropin releasing hormone activity. *WO 2002066477* **2002**.
- (174) Dossetter, A. G.; Kenny, P.; McKerrecher, D.; Wardleworth, M. Amine derivatives of imidazo[1,2-a]pyridine useful as antagonists of gonadotropin releasing hormone. *WO 2002066478* **2002**.
- (175) Lundquist, J. T.; Pelletier, J. C.; Vera, M. D. Preparation of piperazinyimidazopyridine and piperazinyltriazolopyridine antagonists of gonadotropin releasing hormone receptor for treating cancer and other diseases. *US 2006270848* **2006**.
- (176) Pelletier, J. C. 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor and their preparation and pharmaceutical compositions. *US 2006189618* **2006**.
- (177) Pelletier, J. C.; Rogers, J. F. Preparation of piperazinyl imidazo[4,5-c]pyridines as gonadotropin releasing hormone receptor antagonists for the treatment of cancer. *US 2006189616* **2006**.
- (178) Poitout, L.; Brault, V.; Ferrandis, E.; Thurieau, C. Preparation of benzimidazoles as gonadotropin-releasing hormone receptor antagonists and their use against cancer and other diseases. *FR 2833948* **2003**.
- (179) Green, D. M.; Hauze, D. B.; Mann, C. W.; Pelletier, J. C.; Vera, M. D. Preparation of piperaziny-substituted benzoxazoles and benzothiazoles as orally effective antagonists of gonadotropin releasing hormone receptor for use against sex hormone-dependent tumors and other diseases. *US 2006264631* **2006**.
- (180) Hamamura, K.; Oda, T.; Kusaka, M.; Kanzaki, N. Preparation of quinazoline-2,4(1H,3H)-dione derivatives as gonadotropin-releasing hormone antagonists. *WO 2005019188* **2005**.
- (181) Hamamura, K.; Oda, T.; Kaku, T.; Suzuki, T. Preparation of fused pyrimidine derivative as GnRH antagonists. *WO 2006083005* **2006**.
- (182) Ohno, K.; Miyagi, T.; Ozawa, T.; Fushimi, N. Preparation of fused pyrimidine heterocyclic derivatives as antagonists of gonadotropin releasing hormone (GnRH). *WO 2007046392* **2007**.
- (183) Koppitz, M.; Muhn, H. P.; Shaw, K.; Hess-Stumpp, H.; Paulini, K. Synthesis of tetrahydrocarbazole derivatives for use as ligands for G-protein coupled receptors and antagonists of gonadotropin-releasing hormone for treatment of disease. *WO 2003051837* **2003**.

- (184) Paulini, K.; Gerlach, M.; Guenther, E.; Polymeropoulos, E.; Baasner, S.; Schmidt, P.; Kuehne, R.; Soederhaell, A. Preparation of 1,2,3,4-tetrahydrocarbazoles as gonadotropin-releasing hormone receptor (LHRH) antagonist. *WO 2006005484* **2006**.
- (185) Pierce, J. G.; Parsons, T. F. Glycoprotein hormones: structure and function. *Annu Rev Biochem* **1981**, *50*, 465-495.
- (186) Xie, Y. B.; Wang, H.; Segaloff, D. L. Extracellular domain of lutropin/choriogonadotropin receptor expressed in transfected cells binds choriogonadotropin with high affinity. *J Biol Chem* **1990**, *265*, 21411-21414.
- (187) Loumaye, E.; Martineau, I.; Piazzzi, A.; O'Dea, L.; Ince, S.; Howles, C.; Decosterd, G.; Van Loon, K.; Galazka, A. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. *Hum Reprod* **1996**, *11 Suppl 1*, 95-107; discussion 117-119.
- (188) Dunkel, L.; Jia, X. C.; Nishimori, K.; Boime, I.; Hsueh, A. J. Deglycosylated human chorionic gonadotropin (hCG) antagonizes hCG stimulation of 3',5'-cyclic adenosine monophosphate accumulation through a noncompetitive interaction with recombinant human luteinizing hormone receptors. *Endocrinology* **1993**, *132*, 763-769.
- (189) Roy, S.; Setlur, S.; Gadkari, R. A.; Krishnamurthy, H. N.; Dighe, R. R. Translational fusion of two  $\beta$ -subunits of human chorionic gonadotropin results in production of a novel antagonist of the hormone. *Endocrinology* **2007**, *148*, 3977-3986.
- (190) van Straten, N. C.; Schoonus-Gerritsma, G. G.; van Someren, R. G.; Draaijer, J.; Adang, A. E.; Timmers, C. M.; Hanssen, R. G.; van Boeckel, C. A. The first orally active low molecular weight agonists for the LH receptor: thienopyr(im)idines with therapeutic potential for ovulation induction. *Chembiochem* **2002**, *3*, 1023-6.
- (191) Jäschke, H.; Neumann, S.; Moore, S.; Thomas, C. J.; Colson, A.-O.; Costanzi, S.; Kleinau, G.; Jiang, J.-K.; Paschke, R.; Raaka, B. M.; Krause, G.; Gershengorn, M. C. A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). *J Biol Chem* **2006**, *281*, 9841-9844.
- (192) Benzakour, O.; Kanthou, C.; Dennehy, U.; al Haq, A.; Berg, L. P.; Kakkar, V. V.; Cooper, D. N. Evaluation of the use of the luciferase-reporter-gene system for gene-regulation studies involving cyclic AMP-elevating agents. *Biochem J* **1995**, *309 ( Pt 2)*, 385-387.
- (193) Brasier, A. R.; Tate, J. E.; Habener, J. F. Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines. *Biotechniques* **1989**, *7*, 1116-1122.
- (194) Moore, S.; Jaeschke, H.; Kleinau, G.; Neumann, S.; Costanzi, S.; Jiang, J. K.; Childress, J.; Raaka, B. M.; Colson, A.; Paschke, R.; Krause, G.; Thomas, C. J.; Gershengorn, M. C. Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure-activity relationships and selective binding patterns. *J Med Chem* **2006**, *49*, 3888-3896.
- (195) Janovick, J. A.; Maya-Nunez, G.; Ulloa-Aguirre, A.; Huhtaniemi, I. T.; Dias, J. A.; Verboost, P.; Conn, P. M. Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine. *Mol Cell Endocrinol* **2008**.
- (196) Jorand-Lebrun, C.; Brondyk, B.; Lin, J.; Magar, S.; Murray, R.; Reddy, A.; Shroff, H.; Wands, G.; Weiser, W.; Xu, Q.; McKenna, S.; Brugger, N. Identification, synthesis, and biological evaluation of novel pyrazoles as low molecular weight luteinizing hormone receptor agonists. *Bioorg Med Chem Lett* **2007**, *17*, 2080-2085.
- (197) Timmers, C. M.; Karstens, W. F. J. Preparation of thienopyrimidinecarboxamides, quinazolinecarboxamides, and related compounds as luteinizing hormone agonists. *WO 2002024703* **2002**.
- (198) Fan, Q. R.; Hendrickson, W. A. Structure of human follicle-stimulating hormone in complex with its receptor. *Nature* **2005**, *433*, 269-277.

- (199) Hashimoto, S.; Kimura, K.; Kuramochi, T.; Aoyagi, K.; Hirako, M.; Kawaguchi, M.; Iwata, H.; Hirao, M.; Kitada, K.; Hirasawa, K.; Ueda, M. Responsiveness of rabbits to superovulation treatment by a single injection of follicle-stimulating hormone with aluminum hydroxide gel. *Mol Reprod Dev* **2007**, *74*, 1208-1212.
- (200) Guo, T.; Adang, A. E.; Dolle, R. E.; Dong, G.; Fitzpatrick, D.; Geng, P.; Ho, K. K.; Kultgen, S. G.; Liu, R.; McDonald, E.; McGuinness, B. F.; Saionz, K. W.; Valenzano, K. J.; van Straten, N. C.; Xie, D.; Webb, M. L. Small molecule biaryl FSH receptor agonists. Part 1: lead discovery via encoded combinatorial synthesis. *Bioorg Med Chem Lett* **2004**, *14*, 1713-1716.
- (201) Guo, T.; Adang, A. E.; Dong, G.; Fitzpatrick, D.; Geng, P.; Ho, K. K.; Jibilian, C. H.; Kultgen, S. G.; Liu, R.; McDonald, E.; Saionz, K. W.; Valenzano, K. J.; van Straten, N. C.; Xie, D.; Webb, M. L. Small molecule biaryl FSH receptor agonists. Part 2: lead optimization via parallel synthesis. *Bioorg Med Chem Lett* **2004**, *14*, 1717-1720.
- (202) Maclean, D.; Holden, F.; Davis, A. M.; Scheurman, R. A.; Yanofsky, S.; Holmes, C. P.; Fitch, W. L.; Tsutsui, K.; Barrett, R. W.; Gallop, M. A. Agonists of the follicle stimulating hormone receptor from an encoded thiazolidinone library. *J Comb Chem* **2004**, *6*, 196-206.
- (203) Wrobel, J.; Jetter, J.; Kao, W.; Rogers, J.; Di, L.; Chi, J.; Perez, M. C.; Chen, G. C.; Shen, E. S. 5-Alkylated thiazolidinones as follicle-stimulating hormone (FSH) receptor agonists. *Bioorg Med Chem* **2006**, *14*, 5729-5741.
- (204) Arey, B. J.; Yanofsky, S. D.; Claudia Perez, M.; Holmes, C. P.; Wrobel, J.; Gopalsamy, A.; Stevis, P. E.; Lopez, F. J.; Winneker, R. C. Differing pharmacological activities of thiazolidinone analogs at the FSH receptor. *Biochem Biophys Res Commun* **2008**, *368*, 723-728.
- (205) Albanese, C.; Christin-Maitre, S.; Sluss, P. M.; Crowley, W. F.; Jameson, J. L. Development of a bioassay for FSH using a recombinant human FSH receptor and a cAMP responsive luciferase reporter gene. *Mol Cell Endocrinol* **1994**, *101*, 211-219.
- (206) Arey, B. J.; Stevis, P. E.; Deecher, D. C.; Shen, E. S.; Frail, D. E.; Negro-Vilar, A.; Lopez, F. J. Induction of promiscuous G protein coupling of the follicle-stimulating hormone (FSH) receptor: a novel mechanism for transducing pleiotropic actions of FSH isoforms. *Mol Endocrinol* **1997**, *11*, 517-526.
- (207) Pelletier, J. C.; Rogers, J.; Wrobel, J.; Perez, M. C.; Shen, E. S. Preparation of highly substituted gamma-lactam follicle stimulating hormone receptor agonists. *Bioorg Med Chem* **2005**, *13*, 5986-5995.
- (208) Van Straten, N. C.; van Berkel, T. H.; Demont, D. R.; Karstens, W. J.; Merckx, R.; Oosterom, J.; Schulz, J.; van Someren, R. G.; Timmers, C. M.; van Zandvoort, P. M. Identification of substituted 6-amino-4-phenyltetrahydroquinoline derivatives: potent antagonists for the follicle-stimulating hormone receptor. *J Med Chem* **2005**, *48*, 1697-1700.
- (209) El Tayer, N.; Reddy, A.; Buckler, D.; Magar, S. Preparation of carbazoles, isoquinolines, indoles, and related compounds as follicle stimulating hormone mimetics for the treatment of infertility. *WO 200008015* **2000**.
- (210) Shroff, H.; Reddy, A. P.; El Tayar, N.; Brugger, N.; Jorand-Lebrun, C. Preparation of pyrazole compounds for treatment of infertility. . *WO 200187287* **2001**.
- (211) Hanssen, R. G. J. M.; Timmers, C. M. Preparation of thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity. *WO 2003020726* **2003**.
- (212) Grima Poveda, P. M.; Karstens, W. F. J.; Timmers, C. M. Preparation of 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolines for treatment of infertility. *WO 2006117368* **2006**.
- (213) Karstens, W. F. J.; Timmers, C. M. Preparation of 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolines for the treatment of infertility. *WO 2006117371* **2006**.
- (214) Timmers, C. M.; Karstens, W. F. J.; Grima Poveda, P. M. Preparation of 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolines for the treatment of infertility. *WO 2006117370* **2006**.
- (215) Santora, V. J.; Covell, J. A.; Hayashi, R.; Webb, R. R. Preparation of isoxazolylthiazoles as ligands of follicle stimulating hormone receptor. *WO 2005087765* **2005**.

- (216) Daugherty, R. L.; Cockett, A. T.; Schoen, S. R.; Sluss, P. M. Suramin inhibits gonadotropin action in rat testis: implications for treatment of advanced prostate cancer. *J Urol* **1992**, *147*, 727-732.
- (217) Wrobel, J.; Green, D.; Jetter, J.; Kao, W.; Rogers, J.; Perez, M. C.; Hardenburg, J.; Deecher, D. C.; Lopez, F. J.; Arey, B. J.; Shen, E. S. Synthesis of (bis)sulfonic acid, (bis)benzamides as follicle-stimulating hormone (FSH) antagonists. *Bioorg Med Chem* **2002**, *10*, 639-656.
- (218) Arey, B. J.; Deecher, D. C.; Shen, E. S.; Stevis, P. E.; Meade, E. H., Jr.; Wrobel, J.; Frail, D. E.; Lopez, F. J. Identification and characterization of a selective, nonpeptide follicle-stimulating hormone receptor antagonist. *Endocrinology* **2002**, *143*, 3822-3829.
- (219) Hanssen, R. G. J. M.; Timmers, C. M.; Kelder, J. Published LH: Preparation of glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity. *WO 2003020727* **2003**.
- (220) Beindl, W.; Mitterauer, T.; Hohenegger, M.; IJzerman, A. P.; Nanoff, C.; Freissmuth, M. Inhibition of receptor/G protein coupling by suramin analogues. *Mol Pharmacol* **1996**, *50*, 415-423.
- (221) Chung, W. C.; Kermode, J. C. Suramin disrupts receptor-G protein coupling by blocking association of G protein  $\alpha$  and  $\beta\gamma$  subunits. *J Pharmacol Exp Ther* **2005**, *313*, 191-198.
- (222) Coats, S. J.; Hlasta, D. J.; Lantern, C. L.; Macielag, M. J.; Rivero, R.; Fitzpatrick, L. J.; Pan, K. Synthesis of substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone. *WO 200147875* **2001**.
- (223) Magar, S.; Goutopoulos, A.; Liao, Y.; Schwarz, M.; Russell, T. J. Preparation of piperazine derivatives for the treatment of mammalian infertility. *WO 2004031182* **2004**.
- (224) Failli, A.; Heffernan, G. D.; Santilli, A. A.; Quagliato, D. A.; Coghlan, R. D.; Andrae, P. M.; Croce, S. C.; Shen, E. S.; Trybulski, E. J. Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists. *WO 2006135687* **2006**.
- (225) Failli, A. A.; Quagliato, D.; Andrae, P.; Heffernan, G. D.; Coghlan, R. D.; Shen, E. S. Pyrrolobenzodiazepine arylcarboxamides and process for preparation thereof as follicle-stimulating hormone receptor antagonists for prevention of fertility in female and male mammals. *US 2006199806* **2006**.
- (226) Failli, A. A.; Quagliato, D. A.; Heffernan, G.; Coghlan, R. D.; Shen, E. S. Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (FSH-R) antagonists and their preparation, pharmaceutical compositions and use as female contraceptive. *US 2006258645* **2006**.
- (227) Failli, A. A.; Santilli, A. A.; Quagliato, D. A.; Shen, E. S. Pyrrolobenzodiazepines and heteroaryl, aryl and cycloalkylamino ketone derivatives as follicle stimulating hormone receptor (FSH-R) antagonists and their preparation, pharmaceutical compositions and use as female contraceptives. *US 20060258644* **2006**.
- (228) Wortmann, L.; Cleve, A.; Muhn, H.-P.; Langer, G.; Schrey, A.; Kuehne, R.; Menzenbach, B.; Koppitz, M.; Kosemund, D. Preparation of acyltryptophanols as FSH antagonists. *WO 2007017289* **2007**.
- (229) Ohtaki, T.; Shintani, Y.; Honda, S.; Matsumoto, H.; Hori, A.; Kanehashi, K.; Terao, Y.; Kumano, S.; Takatsu, Y.; Masuda, Y.; Ishibashi, Y.; Watanabe, T.; Asada, M.; Yamada, T.; Suenaga, M.; Kitada, C.; Usuki, S.; Kurokawa, T.; Onda, H.; Nishimura, O.; Fujino, M. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. *Nature* **2001**, *411*, 613-617.
- (230) Niida, A.; Wang, Z.; Tomita, K.; Oishi, S.; Tamamura, H.; Otaka, A.; Navenot, J. M.; Broach, J. R.; Peiper, S. C.; Fujii, N. Design and synthesis of downsized metastin (45-54) analogs with maintenance of high GPR54 agonistic activity. *Bioorg Med Chem Lett* **2006**, *16*, 134-137.
- (231) Tomita, K.; Niida, A.; Oishi, S.; Ohno, H.; Cluzeau, J.; Navenot, J.-M.; Wang, Z.-X.; Peiper, S. C.; Fujii, N. Structure-activity relationship study on small peptidic GPR54 agonists. *Bioorg Med Chem* **2006**, *14*, 7595-7603.
- (232) Orsini, M. J.; Klein, M. A.; Beavers, M. P.; Connolly, P. J.; Middleton, S. A.; Mayo, K. H. Metastin (KiSS-1) mimetics identified from peptide structure-activity relationship-derived pharmacophores and directed small molecule database screening. *J Med Chem* **2007**, *50*, 462-471.

- (233) Schally, A. V.; Arimura, A.; Kastin, A. J.; Matsuo, H.; Baba, Y.; Redding, T. W.; Nair, R. M.; Debeljuk, L.; White, W. F. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. *Science* **1971**, *173*, 1036-1038.
- (234) Armer, R. E.; Smelt, K. H. Non-peptidic GnRH receptor antagonists. *Curr Med Chem* **2004**, *11*, 3017-3028.
- (235) Betz, S. F.; Reinhart, G. J.; Lio, F. M.; Chen, C.; Struthers, R. S. Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor. *J Med Chem* **2006**, *49*, 637-647.
- (236) Soudijn, W.; Van Wijngaarden, I.; IJzerman, A. P. Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. *Drug Discov Today* **2004**, *9*, 752-758.
- (237) Gao, Z. G.; IJzerman, A. P. Allosteric modulation of A<sub>2A</sub> adenosine receptors by amiloride analogues and sodium ions. *Biochem Pharmacol* **2000**, *60*, 669-676.
- (238) Cragoe, E. J., Jr.; Woltersdorf, O. W., Jr.; Bicking, J. B.; Kwong, S. F.; Jones, J. H. Pyrazine diuretics. II. N-amidino-3-amino-5-substituted 6-halopyrazinecarboxamides. *J Med Chem* **1967**, *10*, 66-75.
- (239) Van der Klein, P. A.; Kourounakis, A. P.; IJzerman, A. P. Allosteric modulation of the adenosine A<sub>1</sub> receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. *J Med Chem* **1999**, *42*, 3629-3635.
- (240) Van den Nieuwendijk, A. M. C. H.; Pietra, D.; Heitman, L.; Göblyös, A.; IJzerman, A. P. Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. *J Med Chem* **2004**, *47*, 663-672.
- (241) Furuya, S.; Matsumoto, S.; Hayase, Y.; Suzuki, N.; Imada, T. Thienopyridine derivatives, their production and use. *WO 9741126* **1997**.
- (242) Sun, E. T.; Anderson, M. B.; Anderes, K. L.; Christie, L. C.; Do, Q.-Q. T.; Feng, J.; Goetzen, T.; Hong, Y.; Iatsimirskaia, E. A.; Li, H.; Luthin, D. R.; Paderes, G. D.; Pathak, V. P. Non-peptide GnRH agents, pharmaceutical compositions and methods for their use, and processes for preparing them and their intermediates. *WO 2002098363* **2002**.
- (243) Oosterom, J.; van Doornmalen, E. J.; Lobregt, S.; Blomenrohr, M.; Zaman, G. J. High-throughput screening using beta-lactamase reporter-gene technology for identification of low-molecular-weight antagonists of the human gonadotropin releasing hormone receptor. *Assay Drug Dev Technol* **2005**, *3*, 143-154.
- (244) Smith, P. K.; Krohn, R. I.; Hermanson, G. T.; Mallia, A. K.; Gartner, F. H.; Provenzano, M. D.; Fujimoto, E. K.; Goeke, N. M.; Olson, B. J.; Klenk, D. C. Measurement of protein using bicinchoninic acid. *Anal Biochem* **1985**, *150*, 76-85.
- (245) Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K<sub>1</sub>) and the concentration of inhibitor which causes 50 per cent inhibition (I<sub>50</sub>) of an enzymatic reaction. *Biochem Pharmacol* **1973**, *22*, 3099-108.
- (246) Lefkowitz, R. J.; De Lean, A.; Hoffman, B. B.; Stadel, J. M.; Kent, R.; Michel, T.; Limbird, L. Molecular pharmacology of adenylate cyclase-coupled alpha- and beta-adrenergic receptors. *Adv Cyclic Nucleotide Res* **1981**, *14*, 145-61.
- (247) Beckers, T.; Bernd, M.; Kutscher, B.; Kuhne, R.; Hoffmann, S.; Reissmann, T. Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor. *Biochem Biophys Res Commun* **2001**, *289*, 653-663.
- (248) Bruns, R. F.; Fergus, J. H. Allosteric enhancement of adenosine A<sub>1</sub> receptor binding and function by 2-amino-3-benzoylthiophenes. *Mol Pharmacol* **1990**, *38*, 939-949.
- (249) Horstman, D. A.; Brandon, S.; Wilson, A. L.; Guyer, C. A.; Cragoe, E. J., Jr.; Limbird, L. E. An aspartate conserved among G-protein receptors confers allosteric regulation of α<sub>2</sub>-adrenergic receptors by sodium. *J Biol Chem* **1990**, *265*, 21590-21595.

- (250) Neve, K. A.; Cox, B. A.; Henningsen, R. A.; Spanoyannis, A.; Neve, R. L. Pivotal role for aspartate-80 in the regulation of dopamine D<sub>2</sub> receptor affinity for drugs and inhibition of adenylyl cyclase. *Mol Pharmacol* **1991**, *39*, 733-9.
- (251) Leppik, R. A.; Birdsall, N. J. M. Agonist binding and function at the human  $\alpha_{2A}$ -adrenoceptor: allosteric modulation by amilorides. *Mol Pharmacol* **2000**, *58*, 1091-1099.
- (252) Hoare, S. R.; Strange, P. G. Regulation of D<sub>2</sub> dopamine receptors by amiloride and amiloride analogs. *Mol Pharmacol* **1996**, *50*, 1295-1308.
- (253) Göblyös, A.; de Vries, H.; Brussee, J.; IJzerman, A. P. Synthesis and biological evaluation of a new series of 2,3,5-substituted [1,2,4]-thiadiazoles as modulators of adenosine A<sub>1</sub> receptors and their molecular mechanism of action. *J Med Chem* **2005**, *48*, 1145-1151.
- (254) Fromme, B. J.; Katz, A. A.; Roeske, R. W.; Millar, R. P.; Flanagan, C. A. Role of aspartate<sup>7.32(302)</sup> of the human gonadotropin-releasing hormone receptor in stabilizing a high-affinity ligand conformation. *Mol Pharmacol* **2001**, *60*, 1280-1287.
- (255) Lu, Z. L.; Coetsee, M.; White, C. D.; Millar, R. P. Structural determinants for ligand-receptor conformational selection in a peptide G protein-coupled receptor. *J Biol Chem* **2007**, *282*, 17921-17929.
- (256) Lanzafame, A. A.; Sexton, P. M.; Christopoulos, A. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. *Mol Pharmacol* **2006**, *70*, 736-746.
- (257) Schetz, J. A.; Sibley, D. R. The binding-site crevice of the D<sub>4</sub> dopamine receptor is coupled to three distinct sites of allosteric modulation. *J Pharmacol Exp Ther* **2001**, *296*, 359-363.
- (258) Verma, V.; Mann, A.; Costain, W.; Pontoriero, G.; Castellano, J. M.; Skoblenick, K.; Gupta, S. K.; Pristupa, Z.; Niznik, H. B.; Johnson, R. L.; Nair, V. D.; Mishra, R. K. Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog. *J Pharmacol Exp Ther* **2005**, *315*, 1228-1236.
- (259) Smits, G.; Campillo, M.; Govaerts, C.; Janssens, V.; Richter, C.; Vassart, G.; Pardo, L.; Costagliola, S. Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. *EMBO J* **2003**, *22*, 2692-2703.
- (260) Ascoli, M.; Fanelli, F.; Segaloff, D. L. The lutropin/choriogonadotropin receptor, a 2002 perspective. *Endocr Rev* **2002**, *23*, 141-174.
- (261) Zhang, G.; Huang, N.; Li, Y.-W.; Qi, X.; Marshall, A. P.; Yan, X.-X.; Hill, G.; Rominger, C.; Prakash, S. R.; Bakthavatchalam, R.; Rominger, D. H.; Gilligan, P. J.; Zaczek, R. Pharmacological characterization of a novel nonpeptide antagonist radioligand, ((+/-)-N-[2-Methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([<sup>3</sup>H]SN003)) for corticotropin-releasing factor1 receptors. *J Pharmacol Exp Ther* **2003**, *305*, 57-69.
- (262) Zhang, B.; Salituro, G.; Szalkowski, D.; Li, Z.; Zhang, Y.; Royo, I.; Vilella, D.; Diez, M. T.; Pelaez, F.; Ruby, C.; Kendall, R. L.; Mao, X.; Griffin, P.; Calaycay, J.; Zierath, J. R.; Heck, J. V.; Smith, R. G.; Moller, D. E. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. *Science* **1999**, *284*, 974-977.
- (263) Knudsen, L. B.; Kiel, D.; Teng, M.; Behrens, C.; Bhumralkar, D.; Kodra, J. T.; Holst, J. J.; Jeppesen, C. B.; Johnson, M. D.; de Jong, J. C.; Jorgensen, A. S.; Kercher, T.; Kostrowicki, J.; Madsen, P.; Olesen, P. H.; Petersen, J. S.; Poulsen, F.; Sidemann, U. G.; Sturis, J.; Truesdale, L.; May, J.; Lau, J. Small-molecule agonists for the glucagon-like peptide 1 receptor. *PNAS* **2007**, *104*, 937-942.
- (264) Gerritsma, G. G.; Van Straten, N. C. R.; Adang, A. E. P. Published: Preparation of bicyclic heteroaromatic compounds as LH agonists. *WO 2000061586* **2000**.
- (265) Heitman, L. H.; Mulder-Krieger, T.; Spanjersberg, R. F.; von Frijtag Drabbe Künzel, J. K.; Dalpiaz, A.; IJzerman, A. P. Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A<sub>1</sub> receptors of LUF5831, a novel nonadenosine-like agonist. *Br J Pharmacol* **2006**, *147*, 533-541.

- (266) Modica, M.; Romeo, G.; Materia, L.; Russo, F.; Cagnotto, A.; Mennini, T.; Gaspar, R.; Falkay, G.; Fulop, F. Synthesis and binding properties of novel selective 5-HT<sub>3</sub> receptor ligands. *Bioorg Med Chem* **2004**, *12*, 3891-3901.
- (267) Dai, Y.; Guo, Y.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Ahmed, A. A.; Albert, D. H.; Arnold, L.; Arries, S. S.; Barlozzari, T.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Pease, L. J.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Wishart, N.; Davidsen, S. K.; Michaelides, M. R. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. *J Med Chem* **2005**, *48*, 6066-6083.
- (268) Chambhare, R. V.; Khadse, B. G.; Bobde, A. S.; Bahekar, R. H. Synthesis and preliminary evaluation of some N-[5-(2-furanyl)-2-methyl-4-oxo-4H-thieno[2,3-d]pyrimidin-3-yl]-carboxamide and 3-substituted-5-(2-furanyl)-2-methyl-3H-thieno[2,3-d]pyrimidin-4-ones as antimicrobial agents. *Eur J Med Chem* **2003**, *38*, 89-100.
- (269) Henderson, K. M.; Kieboom, L. E.; McNatty, K. P.; Lun, S.; Heath, D. A. [<sup>125</sup>I]hCG binding to bovine thecal tissue from healthy and atretic antral follicles. *Mol Cell Endocrinol* **1984**, *34*, 91-98.
- (270) Angelova, K.; Narayan, P.; Puett, D. The luteinizing hormone receptor: influence of buffer composition on ligand binding and signaling of wild type and mutant receptors. *Mol Cell Endocrinol* **2003**, *204*, 1-9.
- (271) Bhowmick, N.; Huang, J.; Puett, D.; Isaacs, N. W.; Laphorn, A. J. Determination of residues important in hormone binding to the extracellular domain of the luteinizing hormone/chorionic gonadotropin receptor by site-directed mutagenesis and modeling. *Mol Endocrinol* **1996**, *10*, 1147-1159.
- (272) Powell-Jones, C. H.; Saltiel, A. R.; Thomas, C. G., Jr.; Nayfeh, S. N. Dissociation kinetics of the thyrotropin-receptor complex. Characterization of a slowly dissociable component. *Mol Cell Endocrinol* **1981**, *24*, 219-231.
- (273) Christopoulos, A.; Lanzafame, A.; Ziegler, A.; Mitchelson, F. Kinetic studies of co-operativity at atrial muscarinic M<sub>2</sub> receptors with an "infinite dilution" procedure. *Biochem Pharmacol* **1997**, *53*, 795-800.
- (274) Kim, J.; Wess, J.; van Rhee, A. M.; Schoneberg, T.; Jacobson, K. A. Site-directed mutagenesis identifies residues involved in ligand recognition in the human A<sub>2a</sub> adenosine receptor. *J Biol Chem* **1995**, *270*, 13987-13997.
- (275) Alberts, G. L.; Pregonzer, J. F.; Im, W. B. Identification of transmembrane regions critical for ligand binding to the human D<sub>3</sub> dopamine receptor using various D<sub>3</sub>/D<sub>1</sub> transmembrane chimeras. *Mol Pharmacol* **1998**, *54*, 379-388.
- (276) Soderhall, J. A.; Polymeropoulos, E. E.; Paulini, K.; Gunther, E.; Kuhne, R. Antagonist and agonist binding models of the human gonadotropin-releasing hormone receptor. *Biochem Biophys Res Commun* **2005**, *333*, 568-582.
- (277) Kostenis, E.; Mohr, K. Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. *Trends Pharmacol Sci* **1996**, *17*, 280-283.
- (278) Lombardo, F.; Shalaeva, M. Y.; Tupper, K. A.; Gao, F. ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. *J Med Chem* **2001**, *44*, 2490-2497.
- (279) Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. *Chem Rev* **1995**, *95*, 2457-2483.
- (280) Bharathi, P.; Patel, U.; Kawaguchi, T.; Pesak, D. J.; Moore, J. S. Improvements in the synthesis of phenylacetylene monodendrons including a solid-phase convergent method. *Macromolecules* **1995**, *28*, 5955-5963.
- (281) Chang, L. C. W.; Spanjersberg, R. F.; von Frijtag Drabbe Kunzel, J. K.; Mulder-Krieger, T.; van den Hout, G.; Beukers, M. W.; Brussee, J.; IJzerman, A. P. 2,4,6-Trisubstituted pyrimidines as a new class of selective adenosine A<sub>1</sub> receptor antagonists. *J Med Chem* **2004**, *47*, 6529-6540.

- (282) Chang, L. C. W.; von Frijtag Drabbe Kunzel, J. K.; Mulder-Krieger, T.; Westerhout, J.; Spangenberg, T.; Brussee, J.; IJzerman, A. P. 2,6,8-Trisubstituted 1-deazapurines as adenosine receptor antagonists. *J Med Chem* **2007**, *50*, 828-834.
- (283) Mantri, M.; de Graaf, O.; van Veldhoven, J.; Göblyös, A.; von Frijtag Drabbe Kunzel, J. K.; Mulder-Krieger, T.; Link, R.; de Vries, H.; Beukers, M. W.; Brussee, J.; IJzerman, A. P. 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A<sub>2A</sub> adenosine receptor antagonists. *J Med Chem* **2008**, *51*, 4449-4455.
- (284) Göblyös, A.; Gao, Z. G.; Brussee, J.; Connestari, R.; Santiago, S. N.; Ye, K.; IJzerman, A. P.; Jacobson, K. A. Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A<sub>3</sub> adenosine receptor. *J Med Chem* **2006**, *49*, 3354-3361.
- (285) Price, M. R.; Baillie, G. L.; Thomas, A.; Stevenson, L. A.; Easson, M.; Goodwin, R.; McLean, A.; McIntosh, L.; Goodwin, G.; Walker, G.; Westwood, P.; Marrs, J.; Thomson, F.; Cowley, P.; Christopoulos, A.; Pertwee, R. G.; Ross, R. A. Allosteric modulation of the cannabinoid CB<sub>1</sub> receptor. *Mol Pharmacol* **2005**, *68*, 1484-1495.
- (286) Figler, H.; Olsson, R. A.; Linden, J. Allosteric enhancers of A<sub>1</sub> adenosine receptors increase receptor-G protein coupling and counteract guanine nucleotide effects on agonist binding. *Mol Pharmacol* **2003**, *64*, 1557-1564.
- (287) Binet, V.; Brajon, C.; Le Corre, L.; Acher, F.; Pin, J.-P.; Prezeau, L. The heptahelical domain of GABA<sub>B2</sub> is activated directly by CGP7930, a positive allosteric modulator of the GABA<sub>B</sub> receptor. *J Biol Chem* **2004**, *279*, 29085-29091.
- (288) Langmead, C. J.; Fry, V. A. H.; Forbes, I. T.; Branch, C. L.; Christopoulos, A.; Wood, M. D.; Herdon, H. J. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M<sub>1</sub> receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. *Mol Pharmacol* **2006**, *69*, 236-246.
- (289) Schwartz, T. W.; Holst, B. Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. *J Recept Signal Transduct Res* **2006**, *26*, 107-128.
- (290) Schwartz, T. W.; Holst, B. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? *Trends Pharmacol Sci* **2007**, *28*, 366-373.
- (291) Costagliola, S.; Urizar, E.; Mendive, F.; Vassart, G. Specificity and promiscuity of gonadotropin receptors. *Reproduction* **2005**, *130*, 275-281.
- (292) Van Tilburg, E. W.; Van der Klein, P. A.; De Groote, M.; Beukers, M. W.; IJzerman, A. P. Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A<sub>1</sub> receptor. *Bioorg Med Chem Lett* **2001**, *11*, 2017-2019.
- (293) Van Muijlwijk-Koezen, J. E.; Timmerman, H.; Vollinga, R. C.; Frijtag von Drabbe Kunzel, J.; De Groote, M.; Visser, S.; IJzerman, A. P. Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. *J Med Chem* **2001**, *44*, 749-762.
- (294) Urwyler, S.; Mosbacher, J.; Lingenhoehl, K.; Heid, J.; Hofstetter, K.; Froestl, W.; Bettler, B.; Kaupmann, K. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid<sub>B</sub> receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. *Mol Pharmacol* **2001**, *60*, 963-971.
- (295) Urwyler, S.; Pozza, M. F.; Lingenhoehl, K.; Mosbacher, J.; Lampert, C.; Froestl, W.; Koller, M.; Kaupmann, K. N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acid<sub>B</sub> receptor function. *J Pharmacol Exp Ther* **2003**, *307*, 322-330.
- (296) Kenakin, T. G-protein coupled receptors as allosteric machines. *Receptors Channels* **2004**, *10*, 51-60.
- (297) Neumann, S.; Kleinau, G.; Costanzi, S.; Moore, S.; Jiang, J.-k.; Raaka, B. M.; Thomas, C. J.; Krause, G.; Gershengorn, M. C. A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. *Endocrinology* **2008**, *149*, 5945-5950.

- (298) Gao, Z. G.; Kim, S. G.; Soltysiak, K. A.; Melman, N.; IJzerman, A. P.; Jacobson, K. A. Selective allosteric enhancement of agonist binding and function at human A<sub>3</sub> adenosine receptors by a series of imidazoquinoline derivatives. *Mol Pharmacol* **2002**, *62*, 81-89.
- (299) Horn, F.; Bettler, E.; Oliveira, L.; Campagne, F.; Cohen, F. E.; Vriend, G. GPCRDB information system for G protein-coupled receptors. *Nucleic Acids Res* **2003**, *31*, 294-297.
- (300) McElroy, W. D.; Seliger, H. H.; White, E. H. Mechanism of bioluminescence, chemiluminescence and enzyme function in the oxidation of firefly luciferin. *Photochem Photobiol* **1969**, *10*, 153-170.
- (301) de Wet, J. R.; Wood, K. V.; DeLuca, M.; Helinski, D. R.; Subramani, S. Firefly luciferase gene: structure and expression in mammalian cells. *Mol Cell Biol* **1987**, *7*, 725-737.
- (302) de Wet, J. R.; Wood, K. V.; Helinski, D. R.; DeLuca, M. Cloning of firefly luciferase cDNA and the expression of active luciferase in *Escherichia coli*. *Proc Natl Acad Sci U S A* **1985**, *82*, 7870-7873.
- (303) Sudhaharan, T.; Reddy, A. R. Opiate analgesics' dual role in firefly luciferase activity. *Biochemistry* **1998**, *37*, 4451-4458.
- (304) Naylor, L. H. Reporter gene technology: the future looks bright. *Biochem Pharmacol* **1999**, *58*, 749-757.
- (305) Gates, B. J.; DeLuca, M. The production of oxyluciferin during the firefly luciferase light reaction. *Arch Biochem Biophys* **1975**, *169*, 616-621.
- (306) Lee, R. T.; Denburg, J. L.; McElroy, W. D. Substrate-binding properties of firefly luciferase. II. ATP-binding site. *Arch Biochem Biophys* **1970**, *141*, 38-52.
- (307) Denburg, J. L.; Lee, R. T.; McElroy, W. D. Substrate-binding properties of firefly luciferase. I. Luciferin-binding site. *Arch Biochem Biophys* **1969**, *134*, 381-394.
- (308) Rocha, S.; Campbell, K. J.; Roche, K. C.; Perkins, N. D. The p53-inhibitor pifithrin- $\alpha$  inhibits firefly luciferase activity in vivo and in vitro. *BMC Mol Biol* **2003**, *4*, 9.
- (309) Niwa, K.; Ohmiya, Y. Inhibitory effect of lipoic acid on firefly luciferase bioluminescence. *Biochem Biophys Res Commun* **2004**, *323*, 625-629.
- (310) Lee, R.; McElroy, W. D. Role and reactivity of sulfhydryl groups in firefly luciferase. *Biochemistry* **1969**, *8*, 130-136.
- (311) Auld, D. S.; Southall, N. T.; Jadhav, A.; Johnson, R. L.; Diller, D. J.; Simeonov, A.; Austin, C. P.; Inglese, J. Characterization of chemical libraries for luciferase inhibitory activity. *J Med Chem* **2008**, *51*, 2372-86.
- (312) Lyon, P. A.; Reese, C. B. Structures of di-N-aryl derivatives of adenosine and 2-amino-pyridine. *J Chem Soc Perkin I* **1974**, 2645-2649.
- (313) Korodi, F. A simple new synthetic method for the preparation of 2-aminoquinolines. *Synthetic Commun* **1991**, *21*, 1841-1846.
- (314) Broxton, T. J.; Deady, L. W.; Pang, Y. T. Intramolecular Catalysis in Basic Methanolysis of N-2-Pyridinylbenzamide and Related Compounds. *J Am Chem Soc* **1977**, *99*, 2268-2271.
- (315) Bumagin, N. A.; Bykov, V. V. Reactions of organoboron compounds with organic halides catalyzed by ligand-less palladium in aqueous media. *Russ J Gen Chem* **1996**, *66*, 1925-1938.
- (316) Herron, D. K.; Goodson, T.; Wiley, M. R.; Weir, L. C.; Kyle, J. A.; Yee, Y. K.; Tebbe, A. L.; Tinsley, J. M.; Mendel, D.; Masters, J. J.; Franciskovich, J. B.; Sawyer, J. S.; Beight, D. W.; Ratz, A. M.; Milot, G.; Hall, S. E.; Klimkowski, V. J.; Wikel, J. H.; Eastwood, B. J.; Towner, R. D.; Gifford-Moore, D. S.; Craft, T. J.; Smith, G. F. 1,2-dibenzamidobenzene inhibitors of human factor Xa. *J Med Chem* **2000**, *43*, 859-872.
- (317) Eggers, P. K.; Fyles, T. M.; Mitchell, K. D. D.; Sutherland, T. Ion channels from linear and branched bola-amphiphiles. *J Org Chem* **2003**, *68*, 1050-1058.
- (318) Thornton, T. J.; Jackman, A. L.; Marsham, P. R.; Oconnor, B. M.; Bishop, J. A. M.; Calvert, A. H. Quinazoline antifolate thymidylate synthase inhibitors - difluoro-substituted benzene-ring analogs. *J Med Chem* **1992**, *35*, 2321-2327.

- (319) Devine, J. H.; Kutuzova, G. D.; Green, V. A.; Ugarova, N. N.; Baldwin, T. O. Luciferase from the east European firefly *Luciola mingrelica*: cloning and nucleotide sequence of the cDNA, overexpression in *Escherichia coli* and purification of the enzyme. *Biochim Biophys Acta* **1993**, *1173*, 121-132.
- (320) Nakatsu, T.; Ichiyama, S.; Hiratake, J.; Saldanha, A.; Kobashi, N.; Sakata, K.; Kato, H. Structural basis for the spectral difference in luciferase bioluminescence. *Nature* **2006**, *440*, 372-376.
- (321) Chenna, R.; Sugawara, H.; Koike, T.; Lopez, R.; Gibson, T. J.; Higgins, D. G.; Thompson, J. D. Multiple sequence alignment with the Clustal series of programs. *Nucleic Acids Res* **2003**, *31*, 3497-3500.
- (322) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J Comp Chem* **1998**, *19*, 1639-1662.
- (323) Sudha, L. V.; Sathyanarayana, D. N. Molecular-conformation of 1,3-pyridylphenylureas by H-1 and C-13 NMR-study. *J Mol Struct* **1985**, *131*, 141-146.
- (324) Topliss, J. G. Utilization of operational schemes for analog synthesis in drug design. *J Med Chem* **1972**, *15*, 1006-1011.
- (325) Pratt, S. D.; David, C. A.; Black-Schaefer, C.; Dandliker, P. J.; Xuei, X.; Warrior, U.; Burns, D. J.; Zhong, P.; Cao, Z.; Saiki, A. Y.; Lerner, C. G.; Chovan, L. E.; Soni, N. B.; Nilius, A. M.; Wagenaar, F. L.; Merta, P. J.; Traphagen, L. M.; Beutel, B. A. A strategy for discovery of novel broad-spectrum antibacterials using a high-throughput *Streptococcus pneumoniae* transcription/translation screen. *J Biomol Screen* **2004**, *9*, 3-11.
- (326) DeLuca, M.; McElroy, W. D. Two kinetically distinguishable ATP sites in firefly luciferase. *Biochem Biophys Res Commun* **1984**, *123*, 764-770.
- (327) Rhodes, W. C.; Mc, E. W. The synthesis and function of luciferyl-adenylate and oxyluciferyl-adenylate. *J Biol Chem* **1958**, *233*, 1528-1537.
- (328) Petrie, C.; Orme, M. W.; Baindur, N.; Robbins, K. G.; Harris, S. M.; Kontoyianni, M.; Hurley, L. H.; Kerwin, S. M.; Mundy, G. R. Preparation of (hetero)aromatic compounds for treating bone deficit conditions. *WO 9715308* **1997**.
- (329) Orme, M. W.; Baindur, N.; Robbins, K. G. Compositions and methods for treating bone deficit conditions. *WO 9817267* **1998**.
- (330) <http://www.fda.gov/cder/Offices/OODP/whatsnew/Degarelix.htm>.
- (331) Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-target residence time and its implications for lead optimization. *Nat Rev Drug Discov* **2006**, *5*, 730-739.
- (332) Tummino, P. J.; Copeland, R. A. Residence time of receptor-ligand complexes and its effect on biological function. *Biochemistry* **2008**, *47*, 5481-5492.
- (333) Sullivan, S. K.; Hoare, S. R. J.; Fleck, B. A.; Zhu, Y. F.; Heise, C. E.; Struthers, R. S.; Crowe, P. D. Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: Implications for structure-activity relationships and insurmountable antagonism. *Biochem Pharmacol* **2006**, *72*, 838-849.
- (334) Seminara, S. B.; Crowley, W. F., Jr. Kisspeptin and GPR54: discovery of a novel pathway in reproduction. *J Neuroendocrinol* **2008**, *20*, 727-731.
- (335) Espinoza-Fonseca, L. M.; Trujillo-Ferrara, J. G. Identification of multiple allosteric sites on the M<sub>1</sub> muscarinic acetylcholine receptor. *FEBS Letters* **2005**, *579*, 6726-6732.
- (336) Espinoza-Fonseca, L. M.; Trujillo-Ferrara, J. G. The existence of a second allosteric site on the M<sub>1</sub> muscarinic acetylcholine receptor and its implications for drug design. *Bioorg Med Chem Lett* **2006**, *16*, 1217-20.
- (337) Avlani, V. A.; Gregory, K. J.; Morton, C. J.; Parker, M. W.; Sexton, P. M.; Christopoulos, A. Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. *J Biol Chem* **2007**, *282*, 25677-25686.

- (338) Nicholls, D. J.; Tomkinson, N. P.; Wiley, K. E.; Brammall, A.; Bowers, L.; Grahames, C.; Gaw, A.; Meghani, P.; Shelton, P.; Wright, T. J.; Mallinder, P. R. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. *Mol Pharmacol* **2008**, *74*, 1193-1202.
- (339) Andrews, G.; Jones, C.; Wreggett, K. A. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. *Mol Pharmacol* **2008**, *73*, 855-867.

